Tameka Villa
Primary Care · Newark, NJNPI 1942708698
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.9% of the total across 321 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,647, 4.8 times the $344 reported in 2021. Among primary care clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 321 payments — averaging $16.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- United Therapeutics Corporation$711
- Actelion Pharmaceuticals US, Inc.$612
- Astellas Pharma US Inc$560
- Boehringer Ingelheim$481
- Merck$296
- plus $1K from 18 others
What the payments were for
- Food & beverage$4,92595%
- Education$2645%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 80 | $1,111 |
| United Therapeutics Corporation | 47 | $711 |
| Actelion Pharmaceuticals US, Inc. | 36 | $612 |
| Astellas Pharma US Inc | 20 | $560 |
| Boehringer Ingelheim | 32 | $481 |
| Merck | 18 | $296 |
| Mylan Specialty L.p. | 14 | $234 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $226 |
| AstraZeneca | 11 | $185 |
| Insmed, Inc. | 7 | $118 |
| Sanofi | 8 | $117 |
| Bayer | 7 | $102 |
| Viatris Specialty LLC | 5 | $101 |
| Vifor Pharma, Inc. | 4 | $68 |
| Johnson & Johnson | 4 | $52 |
| Alnylam Pharmaceuticals Inc. | 2 | $36 |
| Mallinckrodt Hospital Products Inc. | 2 | $33 |
| Harmony Biosciences LLC | 2 | $30 |
| ANI Pharmaceuticals, Inc. | 2 | $27 |
| Pulmonx Corporation | 1 | $23 |
| Invivyd Inc | 1 | $18 |
| CMP Pharma, Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
How this compares
$5,189 in reported general payments places this provider in the 90th percentile of 330 primary care providers in New Jersey.
Other primary care in Newark
- Shazam BacchusNewark$7K
- Iris Acosta AmezquitaNewark$3K
- Michael Zito GovertNeptune$61K
- Roseann BenantiEnglewood$24K
- Marcelo MarinEnglewood$17K
- Jennifer EdwardsPrinceton$14K
- Mary Grace TolentinoJersey City$9K
- Kevin Robert ReyladoNorth Arlington$8K
- Carlo SebelloJersey City$8K
- Karam WehbehPaterson$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.